Report Library
All Reports
Biosimilars and Reimbursement KOL Interview
July 31, 2015
Highlights
For the full KOL Insight report, please download the PDF version at the top of this page.
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
For our disclosures, please read the BioMedTracker Research Standards.
- KOL previously held a senior position at a large Pharmacy Benefit Management (PBM) firm
- 20% is a minimum price discount to justify the enactment of formulary restrictions, but may not be enough
- Clinical effectiveness and equivalence is the number one tenet for Pharmacy and Therapeutics (P&T) committee decisions
- New entrants like Group Purchasing Organizations (GPOs) will be an impactful group amongst payers
- KOL finds rare disease to be an upcoming challenge for healthcare and opportunity for biosimilar development
For the full KOL Insight report, please download the PDF version at the top of this page.
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
For our disclosures, please read the BioMedTracker Research Standards.
| Disease Group Covered: |
Allergy
Autoimmune/immunology Cardiovascular Dermatology Endocrine ENT/Dental Gastroenterology (Non Inflammatory Bowel Disease) Hematology Infectious Disease Metabolic Neurology Not Specified Obstetrics/Gynecology Oncology Ophthalmology Orthopedics Psychiatry Renal Respiratory Rheumatology (Non Autoimmune) Urology |
Additional Resources: